Related references
Note: Only part of the references are listed.Mo1053 A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of a Novel Potassium-Competitive Acid Blocker (P-CAB) TAK-438 in Patients With Erosive Esophagitis
Tsutomu Chiba et al.
GASTROENTEROLOGY (2015)
Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis
Eiji Umegaki et al.
GASTROENTEROLOGY (2014)
Tu1055 TAK-438 Versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated With Low-Dose Aspirin Therapy: Results of a Phase 3 Trial
Takashi Kawai et al.
GASTROENTEROLOGY (2014)
Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori
Kazunari Murakami et al.
GASTROENTEROLOGY (2014)
Tu1054 TAK-438 Versus Lansoprazole 15 mg for Secondary Prevention of Peptic Ulcers Associated With Non-Steroidal Anti-Inflammatory Drug (NSAID) Therapy: Results of a Phase 3 Trial
Yuji Mizokami et al.
GASTROENTEROLOGY (2014)
Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis
Katsuhiko Iwakiri et al.
GASTROENTEROLOGY (2014)
Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers
Hua-Jun Luo et al.
PLOS ONE (2014)
Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
Yasuyoshi Arikawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438)
Jai Moo Shin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)